Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation.

por Xerri, L., Bouabdallah, R., Devilard, E., Hassoun, J., Stoppa, A. M., Birg, F.
Publicado 1998

Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014

por Laforet, M, Jourde-Chiche, N, Haddad, F, Sallee, M, Stoppa, A M, Brunet, P, Dussol, B, Burtey, S, Gondouin, B
Publicado 2016

Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

por Richard, B., Launay-Iliadis, M. C., Iliadis, A., Just-Landi, S., Blaise, D., Stoppa, A. M., Viens, P., Gaspard, M. H., Maraninchi, D., Cano, J. P.
Publicado 1992

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study

por Macro, M., Hulin, C., Vincent, L., Charvet-Rumpler, A., Benboubker, L., Calmettes, C., Stoppa, A.-M., Laribi, K., Clement-Filliatre, L., Zerazhi, H., Honeyman, F., Richez, V., Maloisel, F., Karlin, L., Barrak, J., Chouaid, C., Leleu, X.
Publicado 2023

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

por Bahlis, N J, Corso, A, Mugge, L-O, Shen, Z-X, Desjardins, P, Stoppa, A-M, Decaux, O, de Revel, T, Granell, M, Marit, G, Nahi, H, Demuynck, H, Huang, S-Y, Basu, S, Guthrie, T H, Ervin-Haynes, A, Marek, J, Chen, G, Facon, T
Publicado 2017

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE

por Schavgoulidze, A., Perrot, A., Cazaubiel, T., Leleu, X., Manier, S., Buisson, L., Maheo, S., Do Souto Ferreira, L., Lannes, R., Pavageau, L., Hulin, C., Marolleau, J.-P., Voillat, L., Belhadj, K., Divoux, M., Slama, B., Brechignac, S., Macro, M., Stoppa, A.-M., Sanhes, L., Orsini-Piocelle, F., Fontan, J., Chretien, M.-L., Demarquette, H., Mohty, M., Avet-Loiseau, H., Corre, J.
Publicado 2022